Shilun Yang, Dingkang Xu, Dianhui Zhang, Xiaowen Huang, Simeng Li, Yan Wang, Jing Lu, Daming Wang, Zhen-Ni Guo, Yi Yang, Dewei Ye, Yu Wang, Aimin Xu, Ruby Lai Chong Hoo, Junlei Chang
Reperfusion therapy is currently the most effective treatment for acute ischemic stroke, but often results in secondary brain injury. Adipocyte fatty acid-binding protein (A-FABP, FABP4, or aP2) was shown to critically mediate cerebral ischemia/reperfusion (I/R) injury by exacerbating blood-brain barrier (BBB) disruption. However, no A-FABP inhibitors have been approved for clinical use due to safety issues. Here, we identified the therapeutic effect of levofloxacin, a widely used antibiotic displaying A-FABP inhibitory activity in vitro, on cerebral I/R injury and determined its target specificity and action mechanism in vivo...
December 17, 2023: European Journal of Pharmacology